Aeolus Pharmaceuticl Company Insiders
| AOLS Stock | USD 0.0001 0.00 0.00% |
Aeolus Pharmaceuticl employs about 4 people. The company is managed by 2 executives with a total tenure of roughly 13 years, averaging almost 6.0 years of service per executive, having 2.0 employees per reported executive. Breaking down Aeolus Pharmaceuticl's management performance can provide insight into the firm performance.
| John McManus CEO CEO and Pres |
Aeolus |
Aeolus Pharmaceuticl Management Team Effectiveness
The company has return on total asset (ROA) of (0.903) % which means that it has lost $0.903 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8643) %, meaning that it created substantial loss on money invested by shareholders. Aeolus Pharmaceuticl's management efficiency ratios could be used to measure how well Aeolus Pharmaceuticl manages its routine affairs as well as how well it operates its assets and liabilities.Aeolus Pharmaceuticl Workforce Comparison
Aeolus Pharmaceuticl is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 326,192. Aeolus Pharmaceuticl adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Aeolus Pharmaceuticl Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Aeolus Pharmaceuticl Price Series Summation is a cross summation of Aeolus Pharmaceuticl price series and its benchmark/peer.
Aeolus Pharmaceuticl Notable Stakeholders
An Aeolus Pharmaceuticl stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aeolus Pharmaceuticl often face trade-offs trying to please all of them. Aeolus Pharmaceuticl's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aeolus Pharmaceuticl's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John McManus | CEO and Pres | Profile | |
| Christopher Stanley | VP Operations | Profile |
About Aeolus Pharmaceuticl Management Performance
The success or failure of an entity such as Aeolus Pharmaceuticl often depends on how effective the management is. Aeolus Pharmaceuticl management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aeolus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aeolus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.
Please note, the imprecision that can be found in Aeolus Pharmaceuticl's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aeolus Pharmaceuticl. Check Aeolus Pharmaceuticl's Beneish M Score to see the likelihood of Aeolus Pharmaceuticl's management manipulating its earnings.
Aeolus Pharmaceuticl Workforce Analysis
Traditionally, organizations such as Aeolus Pharmaceuticl use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aeolus Pharmaceuticl within its industry.Aeolus Pharmaceuticl Manpower Efficiency
Return on Aeolus Pharmaceuticl Manpower
| Revenue Per Employee | 519K | |
| Revenue Per Executive | 1M | |
| Net Loss Per Employee | 889.5K | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 790.8K | |
| Working Capital Per Executive | 1.6M |
Additional Tools for Aeolus Pink Sheet Analysis
When running Aeolus Pharmaceuticl's price analysis, check to measure Aeolus Pharmaceuticl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aeolus Pharmaceuticl is operating at the current time. Most of Aeolus Pharmaceuticl's value examination focuses on studying past and present price action to predict the probability of Aeolus Pharmaceuticl's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aeolus Pharmaceuticl's price. Additionally, you may evaluate how the addition of Aeolus Pharmaceuticl to your portfolios can decrease your overall portfolio volatility.